DeepCure to Participate in US 'CRT 2025'... Presentation of Laparoscopic RDN Research Results

DeepCure, a specialized company in laparoscopic renal denervation (RDN) devices, announced on the 10th that it participated in the Cardiovascular Research Technologies (CRT) conference ‘CRT 2025’ held in Washington D.C., USA, on the 8th.

CRT 2025 is a globally prestigious academic conference in the field of cardiovascular research and treatment. It is held from the 8th to the 11th at the Washington Hilton Hotel in Washington D.C., USA.

This conference serves as an important platform for sharing the latest research results and treatment technologies for cardiovascular diseases, bringing together medical professionals, researchers, and industry stakeholders from around the world to exchange knowledge and collaborate. It plays a particularly significant role in promoting innovative research and clinical applications in the cardiovascular field.

At this conference, DeepCure presented under the theme “Twenty Four Week Safety and Efficacy Of A Novel Extravascular Renal Denervation Device In A Porcine Model At An Elevated Temperature Setting.” Changwook Jeong, founder of DeepCure and professor at Seoul National University Hospital, participated as a co-author of this study.

The presenter was Dr. Abraham R. Tzafriri, Director of Research and Innovation at the Center for Biomedical Science and Engineering Technology (CBSET) in the United States. CBSET is the American animal testing institution where DeepCure conducted its large animal preclinical experiments.

A DeepCure representative stated, “Through participation in this CRT conference, we were able to present the safety and efficacy of the laparoscopic RDN device to medical professionals worldwide,” adding, “We will continue to raise awareness of HyperCure and highlight its technological differentiation through important research presentations.”

Meanwhile, DeepCure’s HyperCure is the world’s first laparoscopic RDN device for treating resistant hypertension. It is classified as a Class III medical device by the FDA and is currently undergoing the first pre-market approval (PMA) clinical trial in Korea.

This content was produced with the assistance of AI translation services.